Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Cellectis Stock Down 2.1 %

NASDAQ CLLS opened at $1.87 on Wednesday. Cellectis has a 52 week low of $1.70 and a 52 week high of $3.77. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $103.93 million, a P/E ratio of -1.44 and a beta of 3.10. The stock’s 50-day moving average price is $2.01 and its 200-day moving average price is $2.24.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the previous year, the business posted ($0.31) EPS. On average, equities research analysts predict that Cellectis will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently modified their holdings of the stock. Long Focus Capital Management LLC increased its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the last quarter. First Affirmative Financial Network purchased a new position in shares of Cellectis during the third quarter valued at about $45,000. XTX Topco Ltd bought a new stake in shares of Cellectis in the second quarter worth about $29,000. Finally, Principal Financial Group Inc. lifted its position in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.